AU2001271380A1 - Intramolecularly-quenched near infrared fluorescent probes - Google Patents

Intramolecularly-quenched near infrared fluorescent probes

Info

Publication number
AU2001271380A1
AU2001271380A1 AU2001271380A AU7138001A AU2001271380A1 AU 2001271380 A1 AU2001271380 A1 AU 2001271380A1 AU 2001271380 A AU2001271380 A AU 2001271380A AU 7138001 A AU7138001 A AU 7138001A AU 2001271380 A1 AU2001271380 A1 AU 2001271380A1
Authority
AU
Australia
Prior art keywords
intramolecularly
near infrared
fluorescent probes
infrared fluorescent
quenched near
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001271380A
Inventor
Alexei Bogdanov
Lee Josephson
Umar Mahmood
Ching-Hsuan Tung
Ralph Weissleder
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of AU2001271380A1 publication Critical patent/AU2001271380A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
    • A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0082—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes
    • A61B5/0084—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters
    • A61B5/0086—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence adapted for particular medical purposes for introduction into the body, e.g. by catheters using infrared radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0054—Macromolecular compounds, i.e. oligomers, polymers, dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6841—In situ hybridisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0062—Arrangements for scanning
    • A61B5/0068—Confocal scanning
AU2001271380A 2000-06-27 2001-06-22 Intramolecularly-quenched near infrared fluorescent probes Abandoned AU2001271380A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09604145 2000-06-27
US09/604,145 US6592847B1 (en) 1998-05-14 2000-06-27 Intramolecularly-quenched near infrared flourescent probes
PCT/US2001/019941 WO2002000265A1 (en) 2000-06-27 2001-06-22 Intramolecularly-quenched near infrared fluorescent probes

Publications (1)

Publication Number Publication Date
AU2001271380A1 true AU2001271380A1 (en) 2002-01-08

Family

ID=24418352

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001271380A Abandoned AU2001271380A1 (en) 2000-06-27 2001-06-22 Intramolecularly-quenched near infrared fluorescent probes

Country Status (3)

Country Link
US (3) US6592847B1 (en)
AU (1) AU2001271380A1 (en)
WO (1) WO2002000265A1 (en)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6592847B1 (en) * 1998-05-14 2003-07-15 The General Hospital Corporation Intramolecularly-quenched near infrared flourescent probes
JP4133319B2 (en) 2000-07-14 2008-08-13 ノバダック テクノロジーズ インコーポレイテッド Compact fluorescent endoscope imaging system
US7383076B2 (en) * 2000-11-27 2008-06-03 The General Hospital Corporation Fluorescence-mediated molecular tomography
US20030044353A1 (en) * 2001-01-05 2003-03-06 Ralph Weissleder Activatable imaging probes
AU2002251739A1 (en) * 2001-01-05 2002-07-30 The General Hospital Corporation Activatable imaging probes
AU2003207438A1 (en) * 2002-01-02 2003-07-24 Visen Medical, Inc. Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor
US20060241496A1 (en) 2002-01-15 2006-10-26 Xillix Technologies Corp. Filter for use with imaging endoscopes
EP1485716A1 (en) * 2002-03-11 2004-12-15 Visen Medical, Inc. Optical imaging probes
US7303741B2 (en) 2002-09-23 2007-12-04 General Electric Company Systems and methods for high-resolution in vivo imaging of biochemical activity in a living organism
WO2004064751A2 (en) * 2003-01-16 2004-08-05 St. Johns University New York Nanoparticle based stabilization of ir fluorescent dyes
US20030186345A1 (en) * 2003-01-30 2003-10-02 Hortin Glen L. Macromolecular enzyme substrates
US20080102036A1 (en) * 2003-06-04 2008-05-01 Poss Kirtland G Biocompatible Fluorescent Silicon Nanoparticles
US7985401B2 (en) 2003-10-31 2011-07-26 The Regents Of The University Of California Peptides whose uptake by cells is controllable
US9695251B2 (en) 2003-10-31 2017-07-04 The Regents Of The University Of California Activatable cell penetrating peptides with quenched fluorophores
AU2005265048B2 (en) 2004-06-18 2011-06-16 Elamleh, David R. Intravascular imaging device and uses thereof
US20060039863A1 (en) * 2004-07-22 2006-02-23 Michael Schirner Use of cyanine dyes for the diagnosis of disease associated with angiogenesis
US20060041248A1 (en) * 2004-08-23 2006-02-23 Patton David L Pharmaceutical compositions delivery system and methods
WO2006124648A2 (en) * 2005-05-13 2006-11-23 The University Of North Carolina At Chapel Hill Capsule imaging devices, systems and methods for in vivo imaging applications
US20090209508A1 (en) * 2005-05-16 2009-08-20 Universite De Geneve Compounds for Photochemotherapy
US20090280064A1 (en) * 2005-06-24 2009-11-12 Rao Papineni Transdermal delivery of optical, spect, multimodal, drug or biological cargo laden nanoparticle(s) in small animals or humans
EP1743658A1 (en) * 2005-07-14 2007-01-17 Schering Aktiengesellschaft Optical imaging of rheumatoid arthritis
US8227621B2 (en) * 2005-06-30 2012-07-24 Li-Cor, Inc. Cyanine dyes and methods of use
NO20053354D0 (en) * 2005-07-11 2005-07-11 Amersham Health As Optical imaging contrast agent.
FR2888753B1 (en) 2005-07-21 2008-04-04 Commissariat Energie Atomique TARGET VECTOR WITH ACTIVABLE IMAGING FUNCTION
EP1934202B1 (en) 2005-09-02 2019-01-09 Visen Medical, Inc. Nicotinic acid and picolinic acid derived near-infrared fluorophores
DK1937676T3 (en) * 2005-09-02 2017-03-06 Visen Medical Inc Biocompatible fluorescent imaging compounds
WO2007028037A1 (en) * 2005-09-02 2007-03-08 Visen Medical, Inc. Biocompatible n, n-disubstituted sulfonamide-containing fluorescent dye labels
US20090098057A1 (en) * 2007-10-16 2009-04-16 Shiying Zheng Silica-cored carrier particle
US7565207B2 (en) * 2005-11-22 2009-07-21 Bsd Medical Corporation Apparatus for creating hyperthermia in tissue
US8170643B2 (en) * 2005-11-22 2012-05-01 Bsd Medical Corporation System and method for irradiating a target with electromagnetic radiation to produce a heated region
US20070148094A1 (en) * 2005-12-22 2007-06-28 Uzgiris Egidijus E Polymeric imaging agents and medical imaging methods
EP1973575B1 (en) 2005-12-22 2019-07-24 Visen Medical, Inc. Biocompatible fluorescent metal oxide nanoparticles
US20090303317A1 (en) * 2006-02-07 2009-12-10 Novadaq Technologies Inc. Near infrared imaging
JP2010513476A (en) * 2006-12-20 2010-04-30 ジーイー・ヘルスケア・アクスイェ・セルスカプ Contrast agent
US20100278745A1 (en) * 2006-12-21 2010-11-04 Norbert Lange Compounds for fluorescence imaging
DK2118206T3 (en) 2007-02-09 2018-06-18 Visen Medical Inc POLYCYCLOF COLORS AND APPLICATION THEREOF
WO2008109832A2 (en) * 2007-03-08 2008-09-12 Visen Medical, Inc. Viable near-infrared fluorochrome labeled cells and methods of making and using same
WO2008124834A1 (en) * 2007-04-10 2008-10-16 Stanford University Photoacoustic probes and methods of imaging
EP2148702A2 (en) * 2007-05-16 2010-02-03 GE Healthcare AS Pentamethine cyanine dyes carrying at least three sulfonic acid groups
US20100233676A1 (en) * 2007-06-14 2010-09-16 Kimberly Kelly High affinity fluorochrome binding peptides
DE102007037008B4 (en) * 2007-08-06 2015-09-10 Siemens Aktiengesellschaft Diagnostic substance for use in a method for determining the aggressiveness of a prostate tumor
DE102007039899B3 (en) * 2007-08-23 2009-04-09 Siemens Ag Sensor for enabling the detection of a substance in the body of a living being
JP5448397B2 (en) * 2007-09-07 2014-03-19 キヤノン株式会社 Substrate probe, detection method of enzyme activity by multiple nuclear magnetic resonance method, and imaging method of enzyme activity
DK2244741T3 (en) 2008-01-18 2015-05-26 Visen Medical Inc Fluorescent imaging agents
EP2268319A2 (en) * 2008-03-07 2011-01-05 Universität Ulm Precursors of lipid metabolism for the diagnosis and treatment of cancer
US8685370B2 (en) 2008-03-14 2014-04-01 Visen Medical, Inc. Integrin targeting agents and in-vivo and in-vitro imaging methods using the same
EP2265630B1 (en) 2008-04-14 2014-10-29 The General Hospital Corporation Plectin-1 targeted agents for detection and treatment of pancreatic ductal adenocarcinoma
US20110104056A1 (en) * 2008-06-05 2011-05-05 Isao Hara Novel molecular assembly, molecular probe for molecular imaging and molecular probe for drug delivery system using the same, and molecular imaging system and drug delivery system
US8268977B2 (en) * 2008-11-20 2012-09-18 The Board Of Trustees Of The Leland Stanford Junior University Strongly quenching oligomeric excimer/quencher pairs for detection schemes
US8864821B2 (en) 2008-11-26 2014-10-21 Visen Medical, Inc. Methods and compositions for identifying subjects at risk of developing stent thrombosis
JP5500875B2 (en) * 2009-01-30 2014-05-21 キヤノン株式会社 Novel compound, probe using the novel compound, and contrast agent for fluorescence imaging using the novel compound or the probe
EP2403964B1 (en) 2009-03-02 2021-09-08 Massachusetts Institute of Technology Methods and products for in vivo enzyme profiling
EP2435096A1 (en) * 2009-05-27 2012-04-04 Lumicell Diagnostics, Inc. Methods and systems for spatially identifying abnormal cells
US9155471B2 (en) 2009-05-27 2015-10-13 Lumicell, Inc'. Methods and systems for spatially identifying abnormal cells
EP2454271A4 (en) 2009-07-15 2015-08-12 Univ California Peptides whose uptake in cells is controllable
EP2459053A2 (en) 2009-07-28 2012-06-06 F. Hoffmann-La Roche AG Non-invasive in vivo optical imaging method
US20130142734A1 (en) * 2010-01-12 2013-06-06 Ayelet David Targeted delivery systems for diagnostic applications
US8834846B2 (en) 2010-05-06 2014-09-16 Bruker Biospin Corporation Fluorescent NIRF activatable probes for disease detection
JP6145404B2 (en) 2010-05-07 2017-06-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Diagnostic methods for ex vivo cell detection
JP2013528379A (en) 2010-05-21 2013-07-11 オームクス コーポレーション Detection of cancer by PSA enzyme activity assay
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
MX354016B (en) 2010-09-15 2018-02-07 J Mrsny Randall Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences.
WO2012050896A2 (en) 2010-09-29 2012-04-19 Kansas State University Research Foundation Protease selective supramolecular assemblies
US9265844B2 (en) 2010-12-01 2016-02-23 The Methodist Hospital System Protease degradable polypeptides and uses thereof
US9314304B2 (en) 2010-12-08 2016-04-19 Lumicell, Inc. Methods and system for image guided cell ablation with microscopic resolution
WO2012120004A1 (en) 2011-03-07 2012-09-13 F. Hoffmann-La Roche Ag In vivo selection of therapeutically active antibodies
US20140099264A1 (en) 2011-03-07 2014-04-10 F. Hoffman-La Roche Ag Means and methods for in vivo testing of therapeutic antibodies
US10006916B2 (en) 2011-03-15 2018-06-26 Massachusetts Institute Of Technology Multiplexed detection with isotope-coded reporters
CA2835286C (en) 2011-05-09 2021-03-23 Visen Medical, Inc. Carbonic anhydrase targeting agents and methods of using same
EP3473273A1 (en) 2011-07-29 2019-04-24 Avelas Biosciences, Inc. Selective delivery molecules and methods of use
WO2013148319A1 (en) 2012-03-30 2013-10-03 Visen Medical, Inc. Bacterial imaging agents and methods of using same
CN104955484B (en) 2012-08-15 2019-01-15 文森医学公司 Prostate-specific antigen medicament and its application method for prostate cancer imaging
US9623122B2 (en) * 2012-09-04 2017-04-18 Shimadzu Corporation Molecular assembly using branched amphiphilic block polymer, and drug transportation system
WO2014055253A1 (en) * 2012-10-04 2014-04-10 The General Hospital Corporation Methods of synthesizing and using peg-like fluorochromes
US9650674B2 (en) 2012-10-19 2017-05-16 Bioventures, Llc Nucleic acid probes and methods of using the same
US10029017B2 (en) 2013-01-29 2018-07-24 The Regents Of The University Of California Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug
CN105102484B (en) 2013-01-30 2020-03-10 艾维拉斯生物科学公司 Selective delivery molecules and methods of use
US9439976B2 (en) 2013-02-13 2016-09-13 The Methodist Hospital System Compositions and methods for using cathepsin E cleavable substrates
EP2967280A4 (en) 2013-03-14 2016-09-28 Lumicell Inc Medical imaging device and methods of use
WO2014160037A2 (en) 2013-03-14 2014-10-02 The Regents Of The University Of California Activatable membrane-interacting peptides and methods of use
AU2014228504C1 (en) 2013-03-15 2019-10-03 Visen Medical, Inc. Substituted silaxanthenium red to near-infrared fluorochromes for in vitro and in vivo imaging and detection
EP3489309A1 (en) 2013-03-15 2019-05-29 Visen Medical, Inc. 4,4-disubstituted cyclohexyl bridged heptamethine cyanine dyes and uses thereof
CA2914754A1 (en) 2013-06-07 2014-12-11 Massachusetts Institute Of Technology Affinity-based detection of ligand-encoded synthetic biomarkers
EP3047274A2 (en) 2013-09-20 2016-07-27 Ohmx Corporation Psa enzymatic activity: a new biomarker for assessing prostate cancer aggressiveness
CN103865089B (en) * 2014-03-10 2016-06-08 山东理工大学 A kind of poly(lactic acid) and PPDO improve the method for poly-peptide film kindliness
CN103865087B (en) * 2014-03-10 2016-06-08 山东理工大学 A kind of method that poly-peptide film kindliness is improved by poly(lactic acid) and PPDO
BR112016025866A2 (en) 2014-05-07 2017-12-12 Applied Molecular Transp Llc pharmaceutical composition, method for treating an anti-inflammatory disease in an individual, method for treating an autoimmune disease in an individual, method for treating cancer in an individual, use of a non-naturally occurring fusion molecule, method for treating a disorder metabolic in an individual, method for treating fatty liver disease in an individual, method for treating a growth hormone deficiency disorder in an individual, and polynucleotide encoding a fusion molecule
US20160097082A1 (en) 2014-09-23 2016-04-07 Ohmx Corporation Prostate specific antigen proteolytic activity for clinical use
US10385380B2 (en) 2014-10-02 2019-08-20 The Regents Of The University Of California Personalized protease assay to measure protease activity in neoplasms
US10403621B2 (en) * 2014-10-29 2019-09-03 Taiwan Semiconductor Manufacturing Company, Ltd. Circuit layout, layout method and system for implementing the method
US10596259B2 (en) 2015-05-20 2020-03-24 The Regents Of The University Of California Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
CN105542208A (en) * 2016-03-07 2016-05-04 山东理工大学 Method for improving water resistance and flexibility of polyvinyl alcohol film through polycaprolactone and poly(p-dioxanone)
US10293122B2 (en) 2016-03-17 2019-05-21 Novadaq Technologies ULC Endoluminal introducer with contamination avoidance
US11448643B2 (en) 2016-04-08 2022-09-20 Massachusetts Institute Of Technology Methods to specifically profile protease activity at lymph nodes
US11428689B2 (en) 2016-05-05 2022-08-30 Massachusetts Institute Of Technology Methods and uses for remotely triggered protease activity measurements
US11779661B2 (en) 2016-11-10 2023-10-10 The General Hospital Corporation Theranostic nucleic acid binding fluorescent nanoprobes and uses thereof
US11519905B2 (en) 2017-04-07 2022-12-06 Massachusetts Institute Of Technology Methods to spatially profile protease activity in tissue and sections
KR101930399B1 (en) * 2017-09-20 2018-12-18 한국과학기술연구원 Self-assembling drug nanocomplex of drug conjugated capthepsin B-cleavable peptide for specific tumor cell
RU2665628C1 (en) * 2018-01-25 2018-09-03 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Device for spectral-fluorescence investigation of fluorochrome content
WO2019173332A1 (en) 2018-03-05 2019-09-12 Massachusetts Institute Of Technology Inhalable nanosensors with volatile reporters and uses thereof
DK3762009T3 (en) 2018-03-08 2022-06-20 Applied Molecular Transport Inc TOXIN-DERIVED ADMINISTRATION CONSTRUCTIONS FOR ORAL ADMINISTRATION
WO2019173787A1 (en) 2018-03-08 2019-09-12 Applied Molecular Transport Inc. Toxin-derived delivery constructs for oral delivery
US11028425B2 (en) 2018-06-08 2021-06-08 Glympse Bio, Inc. Diagnosis and monitoring of liver disease
US11732009B2 (en) 2018-06-08 2023-08-22 Glympse Bio, Inc. Activity sensor with tunable analyte
EP3911753A1 (en) 2019-01-17 2021-11-24 Massachusetts Institute of Technology Sensors for detecting and imaging of cancer metastasis
CN114599665A (en) 2019-08-16 2022-06-07 应用分子转运公司 Compositions, formulations and interleukin production and purification
CN111269287B (en) * 2020-02-06 2022-02-15 苏州大学 Activatable optical molecular probe and preparation method and application thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4281645A (en) * 1977-06-28 1981-08-04 Duke University, Inc. Method and apparatus for monitoring metabolism in body organs
US4868103A (en) * 1986-02-19 1989-09-19 Enzo Biochem, Inc. Analyte detection by means of energy transfer
JPH02504672A (en) 1986-12-15 1990-12-27 ブリティッシュ　テクノロジー　グループ　ユーエスエイ，インコーポレイテッド Monomeric phthalocyanine reagent
US5384241A (en) * 1987-09-11 1995-01-24 Enzo Diagnostics, Inc. Specific binding assay compound with inhibitive self-quenching characteristics
US4947850A (en) 1988-03-11 1990-08-14 Trustees Of The University Of Pennsylvania Method and apparatus for imaging an internal body portion of a host animal
US5090415A (en) * 1989-02-14 1992-02-25 Hamamatsu Photonics Kabushiki Kaisha Examination apparatus
US4945239A (en) 1989-03-29 1990-07-31 Center For Innovative Technology Early detection of breast cancer using transillumination
US5136373A (en) * 1989-06-22 1992-08-04 Hamamatsu Photonics K. K. Image processing apparatus
ATE101812T1 (en) * 1989-12-27 1994-03-15 Nestle Sa REACTION PRODUCT OF A GRAFTED DEXTRANOMER AND A PHTHALOCANINE DYE AND ITS USE.
ATE206395T1 (en) 1990-05-15 2001-10-15 Hyperion Inc FLUORESCENT PORPHYRIN AND FLUORESCENT PHTHALOCYANINE-POLYETHYLENE GLYCOL, POLYOL AND SACCHARIDE DERIVATIVES AS FLUORESCENT PROBE
CA2082936C (en) 1990-05-15 2003-09-23 Peter O. G. Arrhenius Fluorescent porphyrin, and fluorescent phthalocyanine-polyethylene glycol, polyol, and saccharide derivatives as fluorescent probes
US5641878A (en) 1991-05-15 1997-06-24 Diatron Corporation Porphyrin, azaporphyrin, and related fluorescent dyes free of aggregation and serum binding
US5846703A (en) 1990-05-15 1998-12-08 Diatron Corporation Fluorescence immunoassays using fluorescent dyes free of aggregation and serum binding
US5699798A (en) * 1990-08-10 1997-12-23 University Of Washington Method for optically imaging solid tumor tissue
US5186173A (en) 1990-08-14 1993-02-16 Drexel University Method for in vivo measurement of oxygen concentration levels
JPH04122248A (en) 1990-09-13 1992-04-22 Res Dev Corp Of Japan Optical tomographic image imaging device
JP3217107B2 (en) 1992-02-14 2001-10-09 科学技術振興事業団 Fluorescence tomogram measurement system
US6397099B1 (en) * 1992-05-18 2002-05-28 Non-Invasive Technology, Inc. Non-invasive imaging of biological tissue
WO1994005203A1 (en) 1992-09-04 1994-03-17 The General Hospital Corporation Biocompatible polymers containing diagnostic or therapeutic moieties
US5421339A (en) * 1993-05-12 1995-06-06 Board Of Regents, The University Of Texas System Diagnosis of dysplasia using laser induced fluoroescence
US6304771B1 (en) * 1993-10-29 2001-10-16 The Trustees Of The University Of Pennsylvania Systems and methods for imaging fluorophores
US5391877A (en) * 1994-01-26 1995-02-21 Marks; Michael A. Combined imaging scanner
US5590660A (en) * 1994-03-28 1997-01-07 Xillix Technologies Corp. Apparatus and method for imaging diseased tissue using integrated autofluorescence
US5650135A (en) 1994-07-01 1997-07-22 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
US6649143B1 (en) * 1994-07-01 2003-11-18 The Board Of Trustees Of The Leland Stanford Junior University Non-invasive localization of a light-emitting conjugate in a mammal
JPH08131445A (en) 1994-11-14 1996-05-28 Hitachi Ltd Optical measuring instrument
DE4445065A1 (en) 1994-12-07 1996-06-13 Diagnostikforschung Inst Methods for in-vivo diagnostics using NIR radiation
DE69627477T2 (en) * 1995-01-03 2004-03-18 Non-Invasive Technology, Inc. OPTICAL COUPLING DEVICE FOR IN-VIVO EXAMINATION OF BIOLOGICAL TISSUES
US5661035A (en) 1995-06-07 1997-08-26 The Regents Of The University Of California Voltage sensing by fluorescence resonance energy transfer
US5865754A (en) * 1995-08-24 1999-02-02 Purdue Research Foundation Office Of Technology Transfer Fluorescence imaging system and method
US5759781A (en) * 1995-12-22 1998-06-02 Yale University Multiparametric fluorescence in situ hybridization
US5952664A (en) * 1997-01-17 1999-09-14 Imaging Diagnostic Systems, Inc. Laser imaging apparatus using biomedical markers that bind to cancer cells
JP3654325B2 (en) * 1997-02-13 2005-06-02 富士写真フイルム株式会社 Fluorescence detection device
US5928625A (en) 1997-03-13 1999-07-27 Mallinckrodt Inc. Method of measuring physiological function
DE19717904A1 (en) * 1997-04-23 1998-10-29 Diagnostikforschung Inst Acid-labile and enzymatically cleavable dye constructs for diagnostics with near infrared light and for therapy
US5876946A (en) 1997-06-03 1999-03-02 Pharmacopeia, Inc. High-throughput assay
US6081322A (en) 1997-10-16 2000-06-27 Research Foundation Of State Of New York NIR clinical opti-scan system
WO2000075633A1 (en) 1997-12-12 2000-12-14 Hamamatsu Photonics K.K. Optical ct device and method of image reformation
DE69907630T2 (en) * 1998-01-22 2004-02-26 Luminex Corp., Austin MICROPARTICLES WITH MULTIPLE FLUORESCENCE SIGNALS
US6205347B1 (en) * 1998-02-27 2001-03-20 Picker International, Inc. Separate and combined multi-modality diagnostic imaging system
US6592847B1 (en) * 1998-05-14 2003-07-15 The General Hospital Corporation Intramolecularly-quenched near infrared flourescent probes
US6083486A (en) 1998-05-14 2000-07-04 The General Hospital Corporation Intramolecularly-quenched near infrared fluorescent probes
US6377842B1 (en) * 1998-09-22 2002-04-23 Aurora Optics, Inc. Method for quantitative measurement of fluorescent and phosphorescent drugs within tissue utilizing a fiber optic probe
US7581191B2 (en) * 1999-11-15 2009-08-25 Xenogen Corporation Graphical user interface for 3-D in-vivo imaging
US6377841B1 (en) * 2000-03-31 2002-04-23 Vanderbilt University Tumor demarcation using optical spectroscopy
US6615063B1 (en) 2000-11-27 2003-09-02 The General Hospital Corporation Fluorescence-mediated molecular tomography
US7383076B2 (en) * 2000-11-27 2008-06-03 The General Hospital Corporation Fluorescence-mediated molecular tomography
US20030044353A1 (en) * 2001-01-05 2003-03-06 Ralph Weissleder Activatable imaging probes
AU2002251739A1 (en) 2001-01-05 2002-07-30 The General Hospital Corporation Activatable imaging probes
US6825928B2 (en) * 2001-12-19 2004-11-30 Wisconsin Alumni Research Foundation Depth-resolved fluorescence instrument

Also Published As

Publication number Publication date
WO2002000265A1 (en) 2002-01-03
US20030219383A1 (en) 2003-11-27
US8486373B2 (en) 2013-07-16
US6592847B1 (en) 2003-07-15
US20060275775A1 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
AU2001271380A1 (en) Intramolecularly-quenched near infrared fluorescent probes
AU2001262847A1 (en) Language-understanding
AU2001292739A1 (en) 1-oxorapamycins
AU2001296554A1 (en) Fluorescence detection
AU2001254546A1 (en) Aminopiperidines
AU2000267458A1 (en) Hypercomputer
AU2001239310A1 (en) Decahydro-isoquinolines
AU2001220246A1 (en) Neckphone
AU2002211620A1 (en) Autoanastomosis
AU2001258349A1 (en) Bisacylguanidine
AU2001296577A1 (en) Chlorophyllases
AU2001279754A1 (en) Indoloquinazolinones
AU2690701A (en) Spectroscopic probe
AU2001272762A1 (en) Photomultiplier
AU2001272764A1 (en) Photomultiplier
AU2001285886A1 (en) 2-guanidino-4-aryl-quinazoline
AU2002211128A1 (en) Step-bike
AU2001290931A1 (en) Ski-snowboard
AU2001293852A1 (en) Sulfonylguanidine
AU2001258924A1 (en) Microsatellite-aflp
AU2002226346A1 (en) 2-aryl-5-trifluoromethylpyridines
AU2001272763A1 (en) Photomultiplier
AU2001237160A1 (en) Laryngoscope
AU2001281921A1 (en) Bdellosomes
AU2001246864A1 (en) Hypotensors